Ocular Therapeutix Makes Strides in Vision Therapy
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company committed to enhancing vision through innovative treatments for eye diseases, has recently announced its significant involvement in several prestigious retina meetings taking place in September. These events will be hosted in key locations, highlighting groundbreaking advancements in retinal therapies.
Key Presentations Scheduled
In line with their mission to improve vision health, Ocular Therapeutix is preparing to present important findings during various sessions at the upcoming retina meetings. One of the highlights is the renowned Retina Society's 57th Annual Scientific Meeting, which will occur from September 11-15 in Lisbon. This meeting serves as a major platform for ophthalmic experts to discuss the latest research and therapeutic strategies related to retinal diseases.
Highlighted Sessions and Presentations
A standout presentation at the Retina Society meeting is titled 52-week Rescue-Free Subjects Treated with Axitinib Hydrogel Implant (OTX-TKI) in the US Phase 1 Clinical Trial for Neovascular Age-Related Macular Degeneration. This session, scheduled for September 13, will be led by Dr. Andrew A. Moshfeghi.
Another significant presentation will focus on the Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR, where Dr. Dennis M. Marcus will unveil one-year results from the HELIOS Phase 1 Trial on September 14.
Further Engagements at the Ophthalmology Futures Forums
After the Retina Society meeting, Ocular Therapeutix will also take part in the Ophthalmology Futures Forums 2024 on September 18 in Barcelona. A key highlight will be a panel discussion led by Dr. Nadia K. Waheed, addressing Tyrosine Kinase Inhibitors and Other Novel Mechanisms for the Treatment of Neovascular AMD. Additionally, Dr. Peter K. Kaiser will provide insights into novel drug delivery methods for posterior segment diseases.
Focus on the EURETINA Congress
Furthermore, the 24th EURETINA Congress, taking place from September 19-22, will prominently feature Ocular Therapeutix. Notably, Dr. Veeral S. Sheth will present the 48-Week Safety and Efficacy Results from the Phase 1 HELIOS trial of Sustained-Release Axitinib Implant (OTX-TKI) for Non-Proliferative Diabetic Retinopathy on September 20.
In addition to this, an audio presentation detailing a Phase 1 Clinical Trial will be available, showcasing findings related to the sustained-release Axitinib Hydrogel Implant for Neovascular Age-Related Macular Degeneration.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is at the forefront of biopharmaceutical innovation aimed at enhancing vision. Their flagship product, AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), plays a crucial role in treating retinal diseases, especially wet age-related macular degeneration (wet AMD). Currently, it is progressing through Phase 3 clinical trials, reflecting Ocular's commitment to redefining treatment options for patients.
In addition to AXPAXLI, Ocular’s diverse pipeline includes the proprietary ELUTYX™ technology, which supports products like DEXTENZA, an FDA-approved corticosteroid for post-operative ocular inflammation. Their ongoing research and clinical efforts also encompass the PAXTRAVA™ implant, aimed at treating open-angle glaucoma.
Stay Connected with Ocular Therapeutix
Ocular Therapeutix's dedication to innovation is evident through their active participation in leading scientific forums. For more information on their projects and progress, stakeholders and interested parties can connect with the company via their official website and social media channels.
For any inquiries, Ocular Therapeutix's Vice President of Investor Relations, Bill Slattery, can be reached at bslattery@ocutx.com.
Frequently Asked Questions
What is the primary focus of Ocular Therapeutix?
Ocular Therapeutix is dedicated to developing innovative therapies aimed at improving vision and treating retinal diseases.
Where are the upcoming presentations taking place?
The presentations will occur at major retina meetings in Portugal and Spain throughout September.
What is AXPAXLI?
AXPAXLI is an axitinib intravitreal implant designed for the treatment of retinal diseases, currently undergoing Phase 3 trials for wet AMD.
Who are the key speakers for Ocular Therapeutix's presentations?
Key presenters include Dr. Andrew A. Moshfeghi, Dr. Dennis M. Marcus, and Dr. Nadia K. Waheed.
How can I learn more about Ocular Therapeutix?
To learn more, you can visit Ocular Therapeutix's website or contact their investor relations team directly.
